Therapy
Blue light
Green light
Turquoise light
Therapy protocol
Protective eyewear
Daily until safe bilirubin levels are established
Table 27.1
First line
Neonatal hyperbilirubinemia | B |
Light-Emitting Diode (LED)
LED is considered a single-color light therapy. The distinctive feature of LED is that it is a broad-spectrum continuous wave of visible light. Blue light is within the spectral range of 407–425 nm (peak 420 nm) and red light 550–700 nm (660 nm). Blue or red light phototherapy can also be considered as second-line acne treatment in pregnant or lactating females [3].
Intense Pulsed Light (IPL)
IPL uses broad spectrum, pulse-delivered polychromatic light. Considerations for the use of IPL in the pediatric population include pain, edema, erythema, crusting and blistering.
Therapy |
IPL |
IPL + PDT (photodynamic therapy) [6] |
Therapy protocol |
Not established (typically three sessions with 3- to 4-week intervals in between) |
Table 27.3
Third line
Acne, non-inflammatory and inflammatory | C |
Photodynamic Therapy (PDT)
PDT utilizes a photosensitizing agent, commonly 5-aminolevulinic acid (ALA), to increase the effect of an ensuing light- (or laser-) based therapy [7]. Considerations for the use of PDT in the pediatric population include pain, burning, swelling, redness, transient hyperpigmentation, and superficial exfoliation. PDT can be considered as an alternative treatment of extensive viral warts in immunosuppressed individuals.
Therapy ALA–PDT |
ALA+ Red-light (B) |
ALA + Blue-light (C) |
ALA + IPL (C) [8] |
Therapy protocol |
20 % ALA moisturizing cream |
0.5 % ALA liposomal spray |
Short (15–30 min) or longer (3 h) incubation time |
Phototherapy
Phototherapy is utilized to treat a variety of photodermatoses, including photoresponsive inflammatory and autoimmune conditions.
UVA Phototherapy
UVA utilizes ultraviolet light in the 320–400 nm wavelength (UVA1 340–400 nm). This long-wave ultraviolet light is often combined with the oral drug psoralen (PUVA). Considerations for the use of PUVA in the pediatric population include the ability of the child to comply with safety procedure and to hold still in a closed booth, ingesting a systemic psoralen and tolerating any associated nausea, and the cumulative risk for the potential development of skin cancer.
Therapy |
UVA |
UVA1 (B) [17] |
UVA + psoralen (PUVA) |
Therapy protocol |
Requires strict 24 h of protective eyewear |
Once to twice weekly treatment sessions; at least 48–72 h apart |
Psoralens can be delivered topically, given as a bath, or orally |
Psoralen is taken 45–60 min prior to UVA exposure |
UVB Phototherapy
UVB is ultraviolet light that falls in the 280–320 nm wavelength spectrum of light. UVB has been found to be an effective, safe, well-tolerated, and practical alternative treatment modality in the pediatric population, and has surpassed PUVA as the phototherapy of choice in some immune mediated skin diseases.
Therapy |
UVA/UVB |
Broadband UVB (bUVB) |
Excimer laser (308 nm) |
Narrowband UVB (311–312 nm) |
Therapy protocol |
Two to three times weekly protocol |
Photopatch Testing
Photopatch testing is used to further investigate patients with a history of photosensitivity. Ultraviolet radiation is employed while undergoing patch testing with various allergens. Before undergoing photopatch testing, it is prudent to rule out the possibility of the patient having another endogenous photosensitivity, such as polymorphous light eruption (PLE).
Therapy |
UVA |
Therapy protocol |
Back is exposed to UV light following patch take down on day 2 (after 24–48 h) |
Extracorporeal Photochemotherapy
Extracorporeal photopheresis (ECP) is used mainly to treat autoimmune diseases by removing abnormal cells from the bloodstream via lymphocyte activation and cell death. The blood is first separated and treated with a photosensitizing agent, and then irradiated with UV light. Following this photodynamic therapy, the blood is then returned to the patient.
Therapy |
8-MOP + UVA |
Therapy protocol |
4 h per day on two consecutive days, each month |
Table 27.9
First line
Mycosis fungoides (erythrodermic) Sezary’s syndrome | D |
Table 27.10
Second line
SLE | C [57] |
Lichen planus (erosive) | D [58] |
Chronic GVHD | E [59] |
CTCL
Stay updated, free articles. Join our Telegram channelFull access? Get Clinical TreeGet Clinical Tree app for offline access |